Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov 17 recruiting now full pipeline

Major Depressive Disorder (MDD): full-pipeline trial registry

17 of 23 indexed Major Depressive Disorder (MDD) trials are currently recruiting.

Corpus placement: #724 of 28,707 conditions by registered trial count.

23 US clinical trials · 17 currently recruiting · #724 of 28,707 conditions by registered trial count

Major Depressive Disorder (MDD): 23 US clinical trials tracked, 17 recruiting.

Major Depressive Disorder (MDD) is the subject of 23 registered US clinical trials on ClinicalTrials.gov, 17 of them currently open to new participants. 6 are in Phase 3-4 (later-stage) and 8 in Phase 1-2 (earlier-stage). The most active sponsor is Stony Brook University, running 2 of these trials.

Enrollment posture brief

Registry condition major-depressive-disorder-mdd

OPEN 17 | RECR 74% | LATE 6 | EARLY 8 | RANK #724 | SPON 2

Nearest open-share peer: Burkitt Lymphoma (74% recruiting · 23 trials)

Major Depressive Disorde (th…74%Breast Cancer Stage II47.8%Advanced Non-Small-Cell Lung39.1%Anxiety Disorder30.4%Barrett's Esophagus26.1%
Open-enrollment share among volume-matched conditions near Major Depressive Disorder (MDD)

Major Depressive Disorder (MDD) lists 17 open slots (74% of 23 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →

Key findings

What ClinicalTrials.gov does not surface for Major Depressive Disorder (MDD) on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.

  1. Major Depressive Disorder (MDD) is recruiting above its size-band peers.

    17 of 23 indexed trials (73.9%) are open to enrollment, against a 39.7% average across 762 conditions with 20-99 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

  2. Sponsorship of Major Depressive Disorder (MDD) trials is spread across many organizations.

    Stony Brook University accounts for 2 of 23 trials (8.7%). 21 distinct sponsors appear on at least one study for this condition label.

  3. Typical Major Depressive Disorder (MDD) enrolment sits around 80 participants.

    Median target enrolment is 80 among the 23 trials that report a genuine target (sentinel values excluded). 12 of those (52.2%) plan for fewer than 100 participants.

  4. Major Depressive Disorder (MDD) research is mostly interventional.

    20 interventional and 3 observational studies make up this index (87% interventional). Study type is sponsor-reported on ClinicalTrials.gov.

Phase 11Phase 27Phase 34Phase 42

Open and recent trials

23 total, page 1 of 1

RECRUITING Phase 3 500 participants

Evaluation of Efficacy and Safety of Milsaperidone as Adjunctive Therapy in Patients With Major Depressive Disorder

Vanda Pharmaceuticals

NCT06830044

RECRUITING Phase 2 360 participants

A Study to Evaluate the Efficacy and Safety of SPT-300 (GlyphAllo) in Participants With Major Depressive Disorder, With or Without Anxious Distress (BUOY-1 Study)

Seaport Therapeutics

NCT07065240

RECRUITING Phase 3 330 participants

A Study of a Deuterated Psilocin Analog (CYB003) in Humans With Major Depressive Disorder

Cybin IRL Limited

NCT06793397

RECRUITING Phase 2 300 participants

A Study to Evaluate the Effectiveness of DT-101 in Patients With Depression

Draig Therapeutics

NCT07300969

RECRUITING 276 participants

Emotional Cognition: Establishing Constructs and Neural-Behavioral Mechanisms in Older Adults With Depression

University of Texas Southwestern Medical Center

NCT05966532

RECRUITING 200 participants

Computer Game, Qualitative, and MEG/EEG Assessment of Serotonergic Psychedelics

Yale University

NCT06624137

RECRUITING NA 200 participants

Home-Based tDCS Treatment Of Major Depressive Disorder

Sooma Medical

NCT06976697

RECRUITING Phase 2 153 participants

ACP-211 Monotherapy for Major Depressive Disorder With Inadequate Antidepressant Response

ACADIA Pharmaceuticals

NCT07284667

RECRUITING 100 participants

Prediction of REsponse to Depression Interventions (Accelerated rTMS) Using Clinical and TD-fNIRS Measurements

Kernel

NCT07294924

RECRUITING NA 80 participants

Neurofeedback to Treat Depression - 2

University of Pennsylvania

NCT07159061

RECRUITING NA 60 participants

Improving Outcomes in Adolescent Inpatient Depression With Deep Transcranial Magnetic Stimulation

Children's Hospital Medical Center, Cincinnati

NCT07217444

RECRUITING Phase 4 42 participants

The Role of mGluR5 in CBT-I

Stony Brook University

NCT07076342

RECRUITING Phase 2 30 participants

Orexin Antagonism for Suicide Risk: A Proof-of-Concept Clinical Trial

Marianne Goodman

NCT06854224

RECRUITING NA 25 participants

Accelerated Intermittent Theta Burst Stimulation for Adolescent and Young Adult Depression With Elevated Suicide Risk

University of California, Davis

NCT07025720

RECRUITING NA 24 participants

Cognitive Rehabilitation for Veterans With MDD-related Cognitive Functioning Deficits

Portland VA Medical Center

NCT06728774

RECRUITING Phase 4 14 participants

PET Imaging Using the Tracer [18F]VAT to Assess the Antidepressant Effect of Nicotine.

Stony Brook University

NCT07095205

RECRUITING NA 10 participants

Spaced Transcranial Direct Current Stimulation for Treatment-Resistant Depression: A Home-Based Feasibility and Safety Study

University of California, San Diego

NCT07217223

ACTIVE NOT RECRUITING Phase 2 195 participants

Study to Evaluate Efficacy and Safety of Ropanicant in MDD Patients

Suven Life Sciences Limited

NCT06836063

ACTIVE NOT RECRUITING Phase 2 24 participants

A Study in Patients With Major Depressive Disorder

Chase Therapeutics Corporation

NCT03642964

COMPLETED Phase 3 425 participants

Effects Of Antidepressants On Sexual Functioning In Adults

GlaxoSmithKline

NCT00051272

COMPLETED Phase 3 70 participants

Switching From Generic Selective Serotonin Reuptake Inhibitors (SSRIs) and Selective Serotonin and Norepinephrine Reuptake Inhibitors (SNRIs) to Three Different Dose Initiation Strategies With Vilazodone

Duke University

NCT02015546

COMPLETED Phase 2 48 participants

Improving Depression Outcome by Enhancing Memory for Cognitive Therapy

University of California, Berkeley

NCT01790919

COMPLETED Phase 1 20 participants

Patient Tolerability Study of GSK163090

GlaxoSmithKline

NCT00559299

Phase Distribution

PhaseTrial count
Phase 1 1
Phase 2 7
Phase 3 4
Phase 4 2

Named interventions

Most-linked intervention names on Major Depressive Disorder (MDD) records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.

Placebo Drug
6 trials
Extended-release Bupropion Hydrochloride Drug
1 trials
GSK163090 Drug
1 trials
Cognitive therapy for depression Behavioral
1 trials
Vilazodone Drug
1 trials
CTC-501 Drug
1 trials
Ropanicant Drug
1 trials
Spaced Transcranial Direct Current Stimulation (tDCS) Device
1 trials

US sites by state

Facility locations filed on Major Depressive Disorder (MDD) trials. A trial with sites in several states counts in each.

California 12 trials
New York 8 trials
Florida 7 trials
Texas 6 trials
Massachusetts 5 trials
Georgia 5 trials
Ohio 4 trials
Connecticut 4 trials

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

What to do with this Major Depressive Disorder (MDD) page

23 registered trials, 17 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.

  • 17 Major Depressive Disorder (MDD) trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
  • Stony Brook University sponsors the most Major Depressive Disorder (MDD) trials on record, review their full trial history before evaluating a specific study. See Stony Brook University's trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Major Depressive Disorder (MDD) condition card totals 23 registered trials; most-linked intervention Placebo; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.